COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study
<b>Background:</b> Allogeneic hematopoietic stem cell transplant (Allo-HSCT) recipients are still at increased risk of severe COVID-19 infection. Vaccination is a critical strategy to protect this population. This real-world prospective cohort study aimed to evaluate the immune response...
Saved in:
| Main Authors: | Emine Merve Savaş, Şeyma Yıldız, Zübeyde Nur Özkurt, Zehra Baltacı, Özlem Güzel Tunçcan, Zeynep Arzu Yeğin, Kayhan Çağlar, Nurdan Köktürk, Gonca Erbaş, Gülendam Bozdayı, Münci Yağcı |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/7/726 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-Term Donor Chimerism Monitoring for Relapse Risk Assessment After Pediatric Allo-HSCT
by: Prażmo A, et al.
Published: (2025-07-01) -
Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment
by: Yue Liu, et al.
Published: (2025-12-01) -
Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report
by: Song Xue, et al.
Published: (2025-01-01) -
Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01) -
Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)
by: M. Dargenio, et al.
Published: (2025-01-01)